J.A. García-Merino
Autonomous University of Madrid
Internal medicinePathologyMagnetic resonance imagingOncologySingle-nucleotide polymorphismRandomized controlled trialIntensive care medicineProspective cohort studyAdverse effectHazard ratioDimethyl fumarateExacerbationTocilizumabTeriflunomidePonesimodGlatiramer acetateOcrelizumabDiseaseOpportunistic infectionMEDLINEDaclizumabImmunosuppressionLaquinimodMultiple sclerosisProgressive multifocal leukoencephalopathyDifferential diagnosisExpanded Disability Status ScaleNatalizumabClinically isolated syndromeNeuromyelitis opticaMulticenter studyInterferon betaIn patientFamily medicineClinical trialPharmacovigilanceBioinformaticsMedicineCohortGastroenterology
32Publications
10H-index
328Citations
Publications 34
Newest
Objective null This study aimed to identify long-term prognostic protein biomarkers associated with disease progression in patients with progressive multiple sclerosis (MS). null Methods null CSF samples were collected from a discovery cohort of 28 patients with progressive MS who participated in a clinical trial with interferon beta. Patients were classified into high and low disability progression phenotypes according to numeric progression rates (NPR) and step-based progression rates (SPR) af...
Source
Relapsing multiple sclerosis (RMS) presents a highly variable clinical evolution among patients, and its management should be personalized. Although there is no cure at present, effective disease-modifying therapies (DMTs) are available. Selection of the most appropriate DMT for each patient is influenced by several clinical, radiological and demographic aspects as well as personal preferences that, at times, are not covered in the regulatory criteria. This may be a source of difficulty, especia...
Source
#1L. Álvarez AyusoH-Index: 1
Last. A. Sánchez GuerreroH-Index: 1
view all 5 authors...
Abstract Introduction Multiple sclerosis (MS) is a chronic disease affecting the central nervous system and is characterised by inflammation, demyelination, gliosis, and axonal damage. The introduction of dimethyl fumarate and teriflunomide has led to an increase in the number of alternative first-line therapies for MS. The objective of this study was to evaluate the economic impact of the incorporation of new oral therapies at the reference unit (CSUR) at Hospital Universitario Puerta de Hierro...
Source
Resumen null null Introduccion null La esclerosis multiple (EM) es una enfermedad cronica del sistema nervioso central que se caracteriza por la existencia de inflamacion, desmielinizacion, gliosis y dano axonal. La introduccion de dimetilfumarato y teriflunomida ha supuesto un aumento de las alternativas terapeuticas en la primera linea de tratamiento de la EM. El objetivo de este estudio fue evaluar el impacto economico de la incorporacion de estas nuevas terapias orales en la Unidad de Refere...
1 CitationsSource
#1Susana Otero-Romero (Autonomous University of Barcelona)H-Index: 12
view all 21 authors...
Resumen Antecedentes La reciente aparicion de terapias de alta efectividad para el tratamiento de la esclerosis multiple (EM), con potencial riesgo de complicaciones infecciosas, obliga plantear estrategias de prevencion y minimizacion de riesgos. La vacunacion constituye una parte esencial del manejo de estos pacientes. Este consenso recoge una serie de pautas y escenarios practicos de vacunacion en pacientes adultos con EM candidatos a tratamiento inmunosupresor. Metodologia Se llevo a cabo un...
2 CitationsSource
#1Susana Otero-Romero (Autonomous University of Barcelona)H-Index: 12
view all 21 authors...
Background The recent development of highly effective treatments for multiple sclerosis (MS) and the potential risk of infectious complications require the development of prevention and risk minimisation strategies. Vaccination is an essential element of the management of these patients. This consensus statement includes a series of recommendations and practical scenarios for the vaccination of adult patients with MS who are eligible for highly effective immunosuppressive treatments. Methodology...
1 CitationsSource
#1Inmaculada Toboso (Hospital Universitario de Canarias)H-Index: 1
Last. Luisa M. VillarH-Index: 32
view all 60 authors...
Overview: We assessed the role of age and disease activity as new factors contributing to establish the risk of progressive multifocal leucoencephalopathy in multiple sclerosis patients treated with natalizumab in 36 University Hospitals in Europe. We performed the study in 1,307 multiple sclerosis patients (70.8% anti-John Cunninghan virus positive antibodies) treated with natalizumab for a median time of 3.28 years. Epidemiological, clinical, and laboratory variables were collected. Lipid-spec...
4 CitationsSource
#2Julia SabinH-Index: 1
#3Victoria GalanH-Index: 4
Last. Yolanda AladroH-Index: 7
view all 25 authors...
BACKGROUND Dimethyl fumarate (DMF) has demonstrated efficacy in phase III studies. However, real-world data are still limited. OBJECTIVE The objective of this study was to describe the profile of patients who receive DMF and to assess the effectiveness of DMF regarding relapses, disability progression, magnetic resonance imaging activity, and NEDA (No Evidence Disease Activity)-3 status in a Spanish population in a real-world setting. METHODS We conducted a multicenter prospective study of patie...
1 CitationsSource
INTRODUCTION: Like every year, after the ECTRIMS Congress, renowned Spanish neurologists who are experts in multiple sclerosis presented the main novelties in research in this field at the Post-ECTRIMS Meeting. AIM: To summarise the content presented at the 12th edition of the Post-ECTRIMS Meeting, which took place in September 2019 in Sevilla and is presented in two parts. DEVELOPMENT: This first part addresses the latest studies on vitamin D deficiency and the discrepancies that currently exis...
Source
BACKGROUND: Dimethyl fumarate (DMF) tolerability and safety in multiple sclerosis (MS) has been analyzed in randomized clinical trials. Real-life studies are needed to assess possible harms of this therapy in a wider MS population. OBJECTIVE: To evaluate DMF tolerability, safety and persistence in MS in a real-world setting. METHODS: We conducted a multicenter prospective study of patients who started DMF, attended in 16 public hospitals of Spain. A specific database was elaborated to collect da...
11 CitationsSource